Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20835450 | 0.88 | FFAR2 (0.41) | RIPK1MAOBMAOA | |
| SCHEMBL20835790 | 0.83 | RIPK1 (0.44) | RIPK1TDP1RECQLALDH1A1L3MBTL1 | |
| SCHEMBL20835443 | 0.82 | RIPK1 (0.42) | RIPK1TDP1ALDH1A1DRD4MAOB | |
| SCHEMBL28521953 | 0.81 | ALDH1A1 (0.42) | RIPK1TDP1RECQLALDH1A1DRD4 | |
| SCHEMBL20835697 | 0.81 | RIPK1 (0.41) | RIPK1ALDH1A1MAOBOPRK1HCRTR2 | |
| SCHEMBL21094369 | 0.76 | RIPK1 (0.45) | RIPK1ALDH1A1MAOBHCRTR2MAOA | |
| SCHEMBL20835763 | 0.74 | CALCRL (0.45) | RIPK1TDP1RECQLALDH1A1DRD4 | |
| SCHEMBL20835444 | 0.74 | CALCRL (0.39) | RIPK1TDP1ALDH1A1DRD4OPRK1 | |
| SCHEMBL20835766 | 0.74 | CALCRL (0.45) | RIPK1TDP1RECQLALDH1A1DRD4 | |
| SCHEMBL20835576 | 0.73 | RIPK1 (0.42) | RIPK1TDP1DRD4MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10995084-B2 | Pyrrolidine derivative | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2021-05-04 | — | — | US | disclosed |
| CN-109476639-B | Pyrrolidine derivatives | 橘生药品工业股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20200299273-A1 | PYRROLIDINE DERIVATIVE | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2020-09-24 | — | — | US | disclosed |
| EP-3459941-A1 | PYRROLIDINE DERIVATIVE | Kissei Pharmaceutical Co., Ltd. (JP) | 2019-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299273-A1 | PYRROLIDINE DERIVATIVE | CALCRL, NPY1R, GRPR | RIPK1 1917/4885TDP1 1452/4885RECQL 2264/4885 |
| US-10995084-B2 | Pyrrolidine derivative | CALCRL, NPY1R, GRPR | RIPK1 1917/4885TDP1 1452/4885RECQL 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.